421 related articles for article (PubMed ID: 21748820)
1. Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer.
Võsa U; Vooder T; Kolde R; Fischer K; Välk K; Tõnisson N; Roosipuu R; Vilo J; Metspalu A; Annilo T
Genes Chromosomes Cancer; 2011 Oct; 50(10):812-22. PubMed ID: 21748820
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer.
Wang ZX; Bian HB; Wang JR; Cheng ZX; Wang KM; De W
J Surg Oncol; 2011 Dec; 104(7):847-51. PubMed ID: 21721011
[TBL] [Abstract][Full Text] [Related]
3. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of microRNA-181b is a potential prognostic marker of non-small cell lung cancer.
Yang J; Liu H; Wang H; Sun Y
Pathol Res Pract; 2013 Aug; 209(8):490-4. PubMed ID: 23827213
[TBL] [Abstract][Full Text] [Related]
5. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis.
Gao W; Yu Y; Cao H; Shen H; Li X; Pan S; Shu Y
Biomed Pharmacother; 2010 Jul; 64(6):399-408. PubMed ID: 20363096
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection.
Patnaik SK; Kannisto E; Knudsen S; Yendamuri S
Cancer Res; 2010 Jan; 70(1):36-45. PubMed ID: 20028859
[TBL] [Abstract][Full Text] [Related]
7. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.
Gallardo E; Navarro A; Viñolas N; Marrades RM; Diaz T; Gel B; Quera A; Bandres E; Garcia-Foncillas J; Ramirez J; Monzo M
Carcinogenesis; 2009 Nov; 30(11):1903-9. PubMed ID: 19736307
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.
Lebanony D; Benjamin H; Gilad S; Ezagouri M; Dov A; Ashkenazi K; Gefen N; Izraeli S; Rechavi G; Pass H; Nonaka D; Li J; Spector Y; Rosenfeld N; Chajut A; Cohen D; Aharonov R; Mansukhani M
J Clin Oncol; 2009 Apr; 27(12):2030-7. PubMed ID: 19273703
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer.
Raponi M; Dossey L; Jatkoe T; Wu X; Chen G; Fan H; Beer DG
Cancer Res; 2009 Jul; 69(14):5776-83. PubMed ID: 19584273
[TBL] [Abstract][Full Text] [Related]
10. miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression.
Fendler A; Jung M; Stephan C; Honey RJ; Stewart RJ; Pace KT; Erbersdobler A; Samaan S; Jung K; Yousef GM
Int J Oncol; 2011 Nov; 39(5):1183-92. PubMed ID: 21769427
[TBL] [Abstract][Full Text] [Related]
11. Identification and classification of differentially expressed genes in non-small cell lung cancer by expression profiling on a global human 59.620-element oligonucleotide array.
Hofmann HS; Bartling B; Simm A; Murray R; Aziz N; Hansen G; Silber RE; Burdach S
Oncol Rep; 2006 Sep; 16(3):587-95. PubMed ID: 16865260
[TBL] [Abstract][Full Text] [Related]
12. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
[TBL] [Abstract][Full Text] [Related]
13. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival.
Silva J; García V; Zaballos Á; Provencio M; Lombardía L; Almonacid L; García JM; Domínguez G; Peña C; Diaz R; Herrera M; Varela A; Bonilla F
Eur Respir J; 2011 Mar; 37(3):617-23. PubMed ID: 20595154
[TBL] [Abstract][Full Text] [Related]
14. Integrative analysis of microRNA, mRNA and aCGH data reveals asbestos- and histology-related changes in lung cancer.
Nymark P; Guled M; Borze I; Faisal A; Lahti L; Salmenkivi K; Kettunen E; Anttila S; Knuutila S
Genes Chromosomes Cancer; 2011 Aug; 50(8):585-97. PubMed ID: 21563230
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA profiling in lung cancer reveals new molecular markers for diagnosis.
Solomides CC; Evans BJ; Navenot JM; Vadigepalli R; Peiper SC; Wang ZX
Acta Cytol; 2012; 56(6):645-54. PubMed ID: 23207443
[TBL] [Abstract][Full Text] [Related]
16. The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non-small cell lung cancer.
Yoon KA; Yoon H; Park S; Jang HJ; Zo JI; Lee HS; Lee JS
J Thorac Cardiovasc Surg; 2012 Oct; 144(4):794-807. PubMed ID: 22818121
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer.
Han CH; Cho JY; Moon JT; Kim HJ; Kim SK; Shin DH; Chang J; Ahn CM; Kim SK; Chang YS
Oncol Rep; 2006 Dec; 16(6):1205-10. PubMed ID: 17089038
[TBL] [Abstract][Full Text] [Related]
18. hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer.
Wang L; Soria JC; Kemp BL; Liu DD; Mao L; Khuri FR
Clin Cancer Res; 2002 Sep; 8(9):2883-9. PubMed ID: 12231532
[TBL] [Abstract][Full Text] [Related]
19. Novel molecular beacons to monitor microRNAs in non-small-cell lung cancer.
Yao Q; Zhang AM; Ma H; Lin S; Wang XX; Sun JG; Chen ZT
Mol Cell Probes; 2012 Oct; 26(5):182-7. PubMed ID: 22796123
[TBL] [Abstract][Full Text] [Related]
20. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]